BioCentury
ARTICLE | Financial News

Milestone raises $55M in series C

August 1, 2017 10:01 PM UTC

Milestone Pharmaceuticals Inc. (Montreal, Quebec) raised $55 million in a series C round led by Novo Holdings A/S (Hellerup, Denmark). New investors Forbion Capital Partners and Tekla Capital Management also participated, as did existing investors Domain Associates, Fonds de solidarité FTQ, BDC Capital, Pappas Capital and GO Capital.

Milestone will use the funds to advance the company's lead candidate, etripamil (MSP-2017), into Phase III testing to treat paroxysmal supraventricular tachycardia (PSVT). The product is an intranasally administered calcium channel blocker...

BCIQ Company Profiles

Milestone Pharmaceuticals Inc.

BCIQ Target Profiles

Calcium channel